GI
TARA icon

GAMMA Investing’s Protara Therapeutics TARA Stock Holding History

GAMMA Investing’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8K Buy
732
+155
+27% +$737 ﹤0.01% 3663
2026
Q1 		$3.01K Buy
+577
New +$3.42K ﹤0.01% 3547

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

GAMMA Investing's TARA Position: Q2 2026 in Review

GAMMA Investing increased its Protara Therapeutics (TARA) stake by 27% in Q2 2026, buying an estimated $737 and bringing the position to 732 shares worth $2.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3663.

GAMMA Investing first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.01K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • GAMMA Investing held 732 shares of Protara Therapeutics worth $2.8K as of Q2 2026.
  • GAMMA Investing bought 155 Protara Therapeutics shares in Q2 2026, an estimated $737.
  • Protara Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3663 holding.
  • GAMMA Investing first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Protara Therapeutics position peaked at $3.01K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.